Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

Lung Cancer

Volumn 81, Issue 1, 2013, Pages 84-90

  Garrido, Pilar ^a   Rosell, Rafael ^b   Arellano, Antonio ^b   Andreu, Francisco ^c   Dómine, Manuel ^d   Perez Casas, Ana ^d   Cardenal, Felipe ^e   Arnaiz, María del Mar ^e   Morán, Teresa ^b   Morera, Rosa ^a   Isla, Dolores ^f   Valencia, Javier ^f   Cobo, Manuel ^g   Delgado, Raquel ^g   García Gómez, Ramón ^h   Calvo, Felipe ^h   Zamora, Javier ^a   Ramos, Alfredo ^a   Massutí, Bartomeu ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d 28400 Madrid   (Spain)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chemotherapy; Concurrent chemoradiation; Consolidation chemotherapy; Induction chemotherapy; Phase II randomized trial; Radiotherapy; Stage III non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; PLATINUM;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HEMOPTYSIS; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 84878979544     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.009     Document Type: Article

References (27)

1. Siegel R., Naishadham D., Jemal A. Cancer Statistics. CA Cancer J Clin 2012, 62:10-29.
2. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
3. Fournel P., Robinet G., Thomas P., Souquet P.J., Léna H., Vergnenégre A., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
4. Aupérin A., Le Péchoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2012, 28:2181-2190.
5. Pfister D., Johnson D., Azzoli C., Sause W., Smith T.J., Baker S., et al. Treatment of unresectable non small cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-335. American Society of Clinical Oncology.
6. Georgoulias V., Ardavanis A., Tsiafaki X., Agelidou A., Mixalopoulou P., Anagnostopoulou O., et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005, 23:2937-2945.
7. Pallis A.G., Polyzos A., Boukovinas I., Agelidou A., Lamvakas L., Tsiafaki X., et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol 2008, 3:505-510.
8. Curran W., Scott C., Langer C., Komaki R., Lee J., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non small cell lung cancer: Radiation Therapy Oncology Group 9410. Proc Am Soc Clin Oncol 2003, 22:621. [#2499].
9. Choy H., DeVore R.F., Hande K.R., Porter L.L., Rosenblatt P.A., Slovis B., et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 2001, 34:441-449.
10. Jain A.K., Hughes R.S., Sandler A.B., Dowlati A., Schwartzberg L.S., Dobbs T., et al. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol 2009, 4:722-727.
11. Senan S., Cardenal F., Vansteenkiste J., Stigt J., Akyol F., De Neve W., et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 2011, 22:553-558.
12. Gandara D.R., Chansky K., Albain K.S., Gaspar L.E., Lara P.N., Kelly K., et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006, 8:116-121.
13. Werner-Wasik M., Paulus R., Curran W.J., Byhardt R. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 2011, 12:245-251.
14. Machtay M., Paulus R., Moughan J., Komaki R., Bradley J.E., Choy H., et al. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 2012, 7:716-722.
15. Wang L., Wu S., Ou G., Bi N., Li W., Ren H., Cao J., et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012, 77:89-96.
16. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5601-5755.
17. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
18. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
19. Vokes E.E., Herdon J.E., Kelly M.J., Cicchetti M.G., Ramnath N., Neill H., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherpy alone for regionally advanced unresectable stage III non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704.
20. Gregory D.L., Hicks R.J., Hogg A., Binns D.S., Shum P.L., Milner A., et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med 2012, 53:1007-1015.
21. Fournel P., Vergnenégre A., Robinet G., Lena H., Gervais R., Le Caer H., et al. Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): randomized phase II trial GFPC-GLOT-IFCT 02-01. J Clin Oncol 2006, [ASCO Annual meeting proceedings: Part I. vol 24, No. 18S (June 20 Supplement), 2006: 7048].
22. Berghmans T., Van Houtte P., Paesmans M., Giner V., Lecomte J., Koumakis G., et al. V. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 2009, 64:187-193.
23. Langer C.J., Paulus R., Curran W., Movsas B., Werner-Wasik M., Komaki R., et al. Rethinking prognostic factors in the era of combined modality therapy for locally advanced non-small cell lung cancer (LA-NSCLC): a retrospective analysis of RTOG Protocols 9410 and 9801. J Thorac Oncol 2007, 2(Suppl. 8). S309 A1-03.
24. Werner-Wasik M., Scott C., Cox J., Sause W.T., Byhardt R.W., Asbell S., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group patients with locally advanced non-small cell lung cancer: identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000, 48:1475-1482.
25. Dehing-Oberije C., De Ruysscher D., van der Weide H., Hochstenbag M., Bootsma G., Geraedts W., et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo) radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:1039-1044.
26. Berghmans T., Paesmans M., Sculier J.P. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011, 3:127-138.
27. Garrido P., Rosell R., Massutí B., Cardenal F., Alberola V., Dómine M., et al. Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer 2009, 10:180-186. Spanish Lung Cancer Group 0008 Investigators.